Classical markers like ER and Ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: Results from the GEICAM/2002-01 phase II study
- Sánchez-Rovira, P.
- Antón, A.
- Barnadas, A.
- Velasco, A.
- Lomas, M.
- Rodríguez-Pinilla, M.
- Ramírez, J.L.
- Ramírez, C.
- Ríos, M.J.
- Castellá, E.
- García-Andrade, C.
- San Antonio, B.
- Carrasco, E.
- Palacios, J.L.
ISSN: 1699-048X, 1699-3055
Ano de publicación: 2012
Volume: 14
Número: 6
Páxinas: 430-436
Tipo: Artigo